Quotient (Quotient) Change In Receivables : $-1.01 Mil (TTM As of Dec. 2022)

View and export this data going back to 2014. Start your Free Trial

What is Quotient Change In Receivables?

Quotient's change in receivables for the quarter that ended in Dec. 2022 was $-1.16 Mil. It means Quotient's Accounts Receivable increased by $1.16 Mil from Sep. 2022 to Dec. 2022 .

Quotient's change in receivables for the fiscal year that ended in Mar. 2022 was $-1.14 Mil. It means Quotient's Accounts Receivable increased by $1.14 Mil from Mar. 2021 to Mar. 2022 .

Quotient's Accounts Receivable for the quarter that ended in Dec. 2022 was $6.65 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Quotient's Days Sales Outstanding for the three months ended in Dec. 2022 was 60.93.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Quotient's liquidation value for the three months ended in Dec. 2022 was $-304.13 Mil.

Quotient Change In Receivables Historical Data

The historical data trend for Quotient's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quotient Change In Receivables Chart

Quotient Annual Data

Trend

Mar13

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Change In Receivables

Get a 7-Day Free Trial

-0.09

-0.64

-2.18

0.57

-1.14

Quotient Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Change In Receivables	Get a 7-Day Free Trial															-1.13	-0.26	0.83	-0.42	-1.16

Quotient Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.01 Mil.

Quotient (OTCPK:QTNTQ) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Quotient's Days Sales Outstanding for the quarter that ended in Dec. 2022 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	6.647	/	9.954	*	91
=	60.93

2. In Ben Graham's calculation of liquidation value, Quotient's accounts receivable are only considered to be worth 75% of book value:

Quotient's liquidation value for the quarter that ended in Dec. 2022 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	11.934	-	328.211	+	0.75 * 6.647	+	0.5 * 14.327
=	-304.13

Quotient Change In Receivables Related Terms

Thank you for viewing the detailed overview of Quotient's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Quotient (Quotient) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Quotient Ltd (OTCPK:QTNTQ) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Business Park Terre Bonne, Route de Crassier 13, Eysins, CHE, 1262

Website

https://www.quotientbd.com

Quotient Ltd is a commercial-stage diagnostics company. It is involved in the development, manufacturing, and commercialization of conventional reagent products used for blood grouping within the global transfusion diagnostics market. The company develops and commercializes the Mosaiq automation platform. Its product portfolio includes Reagent Red Blood Cells, Antisera Products, Whole Blood Controls, and Ancillary Products. The firm operates in Edinburgh, Scotland, Eysins, Switzerland, and Newton, Pennsylvania. It derives the majority of its revenue from the United States.

Executives

Highbridge Capital Management Llc	10 percent owner	277 PARK AVE, 23RD FLOOR, NEW YORK NY 10172
Quotient Holdings Finance Co Ltd	10 percent owner	C/O APPLEBY GLOBAL SERVICES (CAYMAN) LTD, 71 FORT STREET, PO BOX 500, GRAND CAYMAN E9 KY1-1106
Quotient Holdings Newco, Lp	10 percent owner	C/O THE CORPORATION TRUST COMPANY, 1209 ORANGE STREET, WILMINGTON DE 19801
Quotient Holdings Merger Co Ltd	10 percent owner	PO BOX 536, 13-14 ESPLANADE, ST. HELIER Y9 JE4 5UR
Quotient Holdings Gp, Llc	10 percent owner	C/O THE CORPORATION TRUST COMPANY, 1209 ORANGE STREET, WILMINGTON DE 19801
Isabelle Buckle	director	C/O QUOTIENT LIMITED, B1, BUSINESS PARK, TERRE BONNE, ROUTE DE CRASSIER 13, EYSINS V8 1262
Prondzynski Heino Von	director	275 NORTH FIELD DRIVE, LAKE FOREST IL 60045
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Sophie Bechu	director	C/O QUOTIENT LIMITED, BUSINESS PARK TERRE BONNE, EYSINS V8 1262
Frederick Hallsworth	director	THE GARDEN WING, HOUSTON HOUSE, KIRK ROAD, HOUSTON X0 PA6 7AR
Manuel O. Mendez	director, officer: Chief Executive Officer	500 PLAZA DRIVE, SECAUCUS NJ 07094
L John Wilkerson	director, 10 percent owner	C/O GALEN ASSOCIATES, 610 FIFTH AVENUE 5TH FLOOR, NEW YORK NY 10020
Zubeen Shroff	director, 10 percent owner	C/O HALSEY DRUG CO INC, 1827 PACIFIC STREET, BROOKLYN NY 11233
Ali Kiboro	officer: Chief Financial Officer	C/O QUOTIENT LIMITED, B1, BUSINESS PARK TERRE BONNE, EYSINS V8 1262
Brian Mcdonough	director	12521 MARET DRIVE, ST. LOUIS MO 63127